Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock
Travere Therapeutics' Executive Vice President and Chief Commercial Officer, Peter Heerma, sold approximately $17.86 million worth of company stock between September 15 and September 17, 2026. The transactions occurred within a pre-set Rule 10b5-1 trading plan established on June 16, 2026. The shares were sold at prices ranging from $62.05 to $65.31 per share.
This sale came amid TVTX shares trading near their 52-week high of $68.73, following a significant 168% increase over the past year. Despite this, InvestingPro analysis suggests the stock may be overvalued, placing it among the list of the most overvalued companies. Meanwhile, Heerma also purchased common stock by exercising employee stock options, amounting to around $4.05 million.
These acquisitions took place at exercise prices between $8.93 and $26.88 per share. At the end of the transaction period, Heerma's direct ownership of Travere Therapeutics common stock stood at 117,066 shares.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
